Skip to main content

Milestone 7.E

Initiate at least 3 phase III trials with repurposed drugs or drug combinations. Of these at least one trial will be in an asymptomatic at-risk population (e.g., mutation carriers, APOE4 positive, Down Syndrome, high amyloid burden, etc.) and at least one for individuals with advanced disease. Of the trials initiated in patients with advanced disease, at least one trial will target the neuropsychiatric symptoms of Alzheimer’s disease and related dementias.


Success Criteria

  • Comprehensive success/failure analyses of data from at least 3 phase III trials.


Research Implementation Area
Drug Repurposing and Combination Therapy Development
Timeline
2021–2025
Status
In Progress

Implementation Activities

Funding Initiatives

Research Programs and Resources

Research Highlights

Relevant Recommendations